W
William Cruz-Munoz
Researcher at Sunnybrook Research Institute
Publications - 22
Citations - 2735
William Cruz-Munoz is an academic researcher from Sunnybrook Research Institute. The author has contributed to research in topics: Metastasis & Cancer. The author has an hindex of 12, co-authored 20 publications receiving 2538 citations. Previous affiliations of William Cruz-Munoz include University of Toronto & Sunnybrook Health Sciences Centre.
Papers
More filters
Journal ArticleDOI
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
John M.L. Ebos,Christina R. Lee,William Cruz-Munoz,Georg A. Bjarnason,James G. Christensen,Robert S. Kerbel,Robert S. Kerbel +6 more
TL;DR: It is reported that the VEGFR/PDGFR kinase inhibitor sunitinib/SU11248 can accelerate metastatic tumor growth and decrease overall survival in mice receiving short-term therapy in various metastasis assays, including after intravenous injection of tumor cells or after removal of primary orthotopically grown tumors.
Journal ArticleDOI
Mouse models of advanced spontaneous metastasis for experimental therapeutics
TL;DR: Various models of aggressive multi-organ spontaneous metastasis after surgical resection of orthotopically transplanted human tumour xenografts are developed, providing a personal perspective summarizing the prospect of their increased clinical relevance.
Journal ArticleDOI
Development of a preclinical model of spontaneous human melanoma central nervous system metastasis.
TL;DR: These findings represent the first report of spontaneous CNS metastases generated from primary tumors of any human cancer in mice, and the variant cell lines generated should aid studies in the biology and treatment of CNS metastasis, especially of melanoma origin.
Journal ArticleDOI
Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian Cancer
Kae Hashimoto,Shan Man,Ping Xu,William Cruz-Munoz,Terence Tang,Rakesh Kumar,Robert S. Kerbel +6 more
TL;DR: Oral topotecan may be an ideal agent to consider for clinical trial assessment of metronomic chemotherapy for ovarian cancer, especially when combined with an antiangiogenic drug targeting the vascular endothelial growth factor pathway, such as pazopanib.
Journal ArticleDOI
PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis.
Lucia B. Jilaveanu,Fabio Parisi,Meaghan L. Barr,Christopher R. Zito,Christopher R. Zito,William Cruz-Munoz,Robert S. Kerbel,David L. Rimm,Marcus Bosenberg,Ruth Halaban,Yuval Kluger,Harriet M. Kluger +11 more
TL;DR: PLEKHA5 expression in melanoma tumors was associated with early development of brain metastases and inhibition of PLEkHA5 might decrease passage across the BBB and decrease proliferation and survival of melanoma cells both in the brain and in extracerebral sites.